189 related articles for article (PubMed ID: 18622386)
1. N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas.
Mosnier JF; Kandel C; Cazals-Hatem D; Bou-Hanna C; Gournay J; Jarry A; Laboisse CL
Mod Pathol; 2009 Feb; 22(2):182-90. PubMed ID: 18622386
[TBL] [Abstract][Full Text] [Related]
2. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.
Riener MO; Vogetseder A; Pestalozzi BC; Clavien PA; Probst-Hensch N; Kristiansen G; Jochum W
Hum Pathol; 2010 Nov; 41(11):1558-65. PubMed ID: 20621328
[TBL] [Abstract][Full Text] [Related]
3. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
4. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver.
Kozyraki R; Scoazec JY; Flejou JF; D'Errico A; Bedossa P; Terris B; Fiorentino M; Bringuier AF; Grigioni WF; Feldmann G
Gastroenterology; 1996 Apr; 110(4):1137-49. PubMed ID: 8613003
[TBL] [Abstract][Full Text] [Related]
5. Zonula occludens-1, occludin, and E-cadherin protein expression in biliary tract cancers.
Németh Z; Szász AM; Somorácz A; Tátrai P; Németh J; Gyorffy H; Szíjártó A; Kupcsulik P; Kiss A; Schaff Z
Pathol Oncol Res; 2009 Sep; 15(3):533-9. PubMed ID: 19184677
[TBL] [Abstract][Full Text] [Related]
6. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.
Liau JY; Tsai JH; Yuan RH; Chang CN; Lee HJ; Jeng YM
Mod Pathol; 2014 Aug; 27(8):1163-73. PubMed ID: 24406866
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
[TBL] [Abstract][Full Text] [Related]
8. C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis.
Yeh YC; Lei HJ; Chen MH; Ho HL; Chiu LY; Li CP; Wang YC
Am J Surg Pathol; 2017 Dec; 41(12):1630-1641. PubMed ID: 28945626
[TBL] [Abstract][Full Text] [Related]
9. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas.
Akita M; Fujikura K; Ajiki T; Fukumoto T; Otani K; Azuma T; Itoh T; Ku Y; Zen Y
Mod Pathol; 2017 Jul; 30(7):986-997. PubMed ID: 28338651
[TBL] [Abstract][Full Text] [Related]
10. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
[TBL] [Abstract][Full Text] [Related]
11. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
12. TTF-1 and Napsin-A are expressed in a subset of cholangiocarcinomas arising from the gallbladder and hepatic ducts: continued caveats for utilization of immunohistochemistry panels.
Surrey LF; Frank R; Zhang PJ; Furth EE
Am J Surg Pathol; 2014 Feb; 38(2):224-7. PubMed ID: 24418856
[TBL] [Abstract][Full Text] [Related]
13. The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma.
Hooper JE; Morgan TK; Grompe M; Sheppard BC; Troxell ML; Corless CL; Streeter PR
Hum Pathol; 2012 Oct; 43(10):1583-9. PubMed ID: 22406361
[TBL] [Abstract][Full Text] [Related]
14. Tubulin β-III: a novel immunohistochemical marker for intrahepatic peripheral cholangiocarcinoma.
Zen Y; Britton D; Mitra V; Pike I; Sarker D; Itoh T; Heaton N; Quaglia A
Histopathology; 2014 Dec; 65(6):784-92. PubMed ID: 25039376
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis.
Terada T; Nakanuma Y; Sirica AE
Hum Pathol; 1998 Feb; 29(2):175-80. PubMed ID: 9490278
[TBL] [Abstract][Full Text] [Related]
16. Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma.
Tsokos CG; Krings G; Yilmaz F; Ferrell LD; Gill RM
Hum Pathol; 2016 Nov; 57():61-67. PubMed ID: 27396933
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis.
Rullier A; Le Bail B; Fawaz R; Blanc JF; Saric J; Bioulac-Sage P
Am J Surg Pathol; 2000 Jun; 24(6):870-6. PubMed ID: 10843291
[TBL] [Abstract][Full Text] [Related]
18. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM
Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.
Goeppert B; Frauenschuh L; Renner M; Roessler S; Stenzinger A; Klauschen F; Warth A; Vogel MN; Mehrabi A; Hafezi M; Boehmer K; von Deimling A; Schirmacher P; Weichert W; Capper D
Mod Pathol; 2014 Jul; 27(7):1028-34. PubMed ID: 24309328
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver.
Shimonishi T; Miyazaki K; Nakanuma Y
Histopathology; 2000 Jul; 37(1):55-63. PubMed ID: 10931219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
